Corvus Pharmaceuticals Inc

Change company Symbol lookup

Select an option...

CRVS Corvus Pharmaceuticals Inc

NRSN Neurosense Therapeutics Ltd

ACNT Ascent Industries Co

FATH Fathom Digital Manufacturing Corp

PAYX Paychex Inc

WAVD Wavedancer Inc

RNXT RenovoRx Inc

GBNY Generations Bancorp NY Inc

POL Polished.Com Inc

MDGS Medigus Ltd

Go

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on development of immune modulator product candidates with the potential to treat solid cancers, T cell lymphomas, autoimmune, allergic and infectious diseases. Its lead product candidate is CPI-818, a selective, covalent inhibitor of ITK and is in a multi-center Phase 1/1b clinical trial in patients with various malignant T cell lymphomas. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. Its third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73. Its product candidate also includes CPI-182, an Anti-CXCR2 Antibody designed to block inflammation and myeloid suppression.